PMID 18158646
Protocol [2] Rats: Serial dilutions of dihexa in 50% DMSO or water (for dilutions of 50 g/mL or less) are prepared from the stock used to dose the animals to be used for preparation of a standard curve
HPLC purity, mass-spectrometry identity confirmation and a bacterial endotoxin (LAL) result are recorded against the specific lot you receive
(2021), Lancet 397(10286), PubMed 33894838 Statistics from preclinical literature Cagrilintide (development code AM833 ), a long-acting amylin analogue , 32 amino acids, molecular weight 3.795 kDa Developed at Novo Nordisk (Denmark) as part of the CagriSema combination program (cagrilintide + semaglutide) Target: amylin receptors (AMY1, AMY2, AMY3) + secondarily the calcitonin receptor , extended half-life via a C16 fatty acid linker Standard dose in clinical trials: 0.164.5 mg/week subcutaneously (Phase 1b/2) Phase 2 (Enebo 2021, n=96): 17.1 % reduction in body weight with CagriSema 2.4 mg + 2.4 mg over 20 weeks vs 9.8 % with semaglutide alone REDEFINE 1 Phase 3 (2024, preliminary data): 22.7 % weight reduction with CagriSema 2.4 mg/2.4 mg over 68 weeks Status: Phase 3 completed 20242025 , FDA filing expected 20252026 Approximately 25+ peer-reviewed publications in PubMed (20182024) Reference sources (PubMed) Enebo LB
BPC-157 is one peptide
FIGURE 3 3.3 GHK-Cu promoted mucosal healing GHK-Cu treatment significantly enhanced of ZO-1 and Occludin expression in colitic mice, which were downregulated by DSS (Figures 4AC)
